随着2025年国家医保谈判结果的正式落地，114种药品被新纳入目录。对于药企而言，这原本意味着凭借价格让步换取市场放量的黄金期已经开启。然而，在临床一线的报销窗口，一个此前被视为程序性细节的隐忧正迅速放大，并演变为创新药落地的一大梗阻——药品说明书的更新速度，未能跟上临床诊疗方案的演进节奏。这种“说明书滞后”现象，正让许多已经通过重重审核进入医保的创新疗法，陷入“看得见、用得上、报不了”的尴尬境地...
Source Link随着2025年国家医保谈判结果的正式落地，114种药品被新纳入目录。对于药企而言，这原本意味着凭借价格让步换取市场放量的黄金期已经开启。然而，在临床一线的报销窗口，一个此前被视为程序性细节的隐忧正迅速放大，并演变为创新药落地的一大梗阻——药品说明书的更新速度，未能跟上临床诊疗方案的演进节奏。这种“说明书滞后”现象，正让许多已经通过重重审核进入医保的创新疗法，陷入“看得见、用得上、报不了”的尴尬境地...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.